Central serous chorioretinopathy and the sclera: what we have learned so far

被引:4
|
作者
Koizumi, Hideki [1 ]
Imanaga, Naoya [1 ]
Terao, Nobuhiro [1 ]
机构
[1] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara, Nishihara, Okinawa 9030215, Japan
关键词
Central serous chorioretinopathy; Pachychoroid; Sclera; Uveal effusion syndrome; Vortex vein; INDOCYANINE GREEN ANGIOGRAPHY; PHOTODYNAMIC THERAPY; VORTEX VEIN; THICKNESS; LOCULATION; FEATURES; EFFUSION; FLUID;
D O I
10.1007/s10384-024-01101-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Central serous chorioretinopathy (CSC) is a common disorder characterized by serous retinal detachment. Several studies using indocyanine green angiography (ICGA) have revealed that choroidal filling delay, choroidal vascular dilation, and choroidal vascular hyperpermeability are the characteristic findings of CSC. These ICGA findings confirm that choroidal circulatory disturbances are the primary factors in the pathogenesis of CSC. With advancements in optical coherence tomography (OCT), choroidal thickness has been found to be significantly greater in eyes with CSC than in normal eyes. Dilated large choroidal vessels reportedly account for the thickened choroid in eyes with CSC. Although many possible mechanisms and risk factors have been suggested, the pathophysiologic features of choroidal circulatory disturbances and choroidal thickening in eyes with CSC have not yet been fully elucidated. Recently, using anterior segment OCT, we proposed that the sclera may induce choroidal circulatory disturbances since CSC eyes have significantly thicker sclera than do normal eyes. This review summarizes updated information on the close relationship between CSC pathogenesis and the sclera.
引用
收藏
页码:419 / 428
页数:10
相关论文
共 50 条
  • [1] Central serous chorioretinopathy: what we have learnt so far
    Wong, Kah Hie
    Lau, Kin Pong
    Chhablani, Jay
    Tao, Yong
    Li, Qing
    Wong, Ian Y.
    ACTA OPHTHALMOLOGICA, 2016, 94 (04) : 321 - 325
  • [2] Brexit: What Have We Learned So Far?
    Besch, Sophia
    Black, James
    SURVIVAL, 2016, 58 (05) : 59 - 67
  • [3] Fukushima - what have we learned so far?
    Kidd, Steve
    NUCLEAR ENGINEERING INTERNATIONAL, 2011, 56 (685): : 12 - 13
  • [4] Levosimendan: What Have We Learned So Far?
    Giulia Villa
    Guido Tavazzi
    Fabio Guarracino
    Fabio Sangalli
    Current Anesthesiology Reports, 2019, 9 : 234 - 241
  • [5] Acrylamide: What we have learned so far
    Coughlin, JR
    FOOD TECHNOLOGY, 2003, 57 (02) : 100 - 100
  • [6] Levosimendan: What Have We Learned So Far?
    Villa, Giulia
    Tavazzi, Guido
    Guarracino, Fabio
    Sangalli, Fabio
    CURRENT ANESTHESIOLOGY REPORTS, 2019, 9 (03) : 234 - 241
  • [7] The Expression of Insulin in the Central Nervous System: What Have We Learned So Far?
    Dakic, Tamara
    Jevdjovic, Tanja
    Lakic, Iva
    Ruzicic, Aleksandra
    Jasnic, Nebojsa
    Djurasevic, Sinisa
    Djordjevic, Jelena
    Vujovic, Predrag
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [8] MORTGAGE PRICING - WHAT HAVE WE LEARNED SO FAR
    HENDERSHOTT, PH
    AREUEA JOURNAL-JOURNAL OF THE AMERICAN REAL ESTATE & URBAN ECONOMICS ASSOCIATION, 1986, 14 (04): : 497 - 509
  • [9] Neuroinflammation and autism: what have we learned so far?
    Aytulun, Asli
    Unal, Dilek
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES, 2024,
  • [10] DRUG COURTS - WHAT HAVE WE LEARNED SO FAR
    MAHONEY, B
    JUSTICE SYSTEM JOURNAL, 1994, 17 (01) : 127 - 133